Eczematous Dermatitis in the Setting of Hyper-IgE Syndrome Successfully Treated With Omalizumab

Bard, Susan; Paravisini, Alexandra; Avilés-Izquierdo, J.A.; Fernández‐Cruz, Eduardo; Sánchez-Ramón, Silvia

doi:10.1001/archdermatol.2008.510

Cited by 35 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This positive outcome is supported by a case report showing a marked reduction in the use of oral steroids 83. Hyper-IgE syndrome is reported as a possible further application; in one case report, treatment with 450 mg of omalizumab every 2 weeks produced complete resolution of skin manifestations in a 26-year-old woman 84. Once again, omalizumab proved to be effective in disorders unrelated to IgE-mediated hypersensitivity, such as interstitial cystitis,85 bullous pemphigoid,86 chronic rhinosinusitis,87 and aspirin-exacerbated respiratory disease 88…”

Section: Further Therapeutic Activity Of Omalizumab: Off-label Indicamentioning

confidence: 81%

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Incorvaia¹,

Mauro

Russello

et al. 2014

DDDT

View full text Add to dashboard Cite

A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. In recent years, some studies have shown that omalizumab is effective also in nonallergic asthma. Effects on the complex signaling mechanisms leading to activation of effector cells and to mediator release may account for this outcome. Indeed, omalizumab has been reported to be effective in a number of IgE-mediated and non-IgE-mediated disorders. Concerning the former, clinical efficacy has been observed in rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, and anaphylaxis. In addition, omalizumab has been demonstrated to be able to prevent systemic reactions to allergen immunotherapy, thus enabling completion of treatment in patients who otherwise would have to stop it. Concerning non-IgE-mediated disorders, omalizumab has been reported to be effective in nasal polyposis, autoimmune urticaria, chronic idiopathic urticaria, physical urticaria, idiopathic angioedema, and mastocytosis. Current indications for treatment with omalizumab are confined to severe allergic asthma. Consequently, any other prescription can only be off-label. However, it is reasonable to expect that the use of omalizumab will be approved for particularly important indications, such as anaphylaxis, in the near future.

show abstract

Section: Further Therapeutic Activity Of Omalizumab: Off-label Indicamentioning

confidence: 81%

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Incorvaia¹,

Mauro

Russello

et al. 2014

DDDT

View full text Add to dashboard Cite

show abstract

“…There are scarce reports of improvement of clinical and laboratory indicators with administration of IFN-g. 218,258,260 However, evidence is not sufficient to consider this to be standard therapy for HIES. There are isolated case reports with rituximab (for lymphoma) 281 or omalizumab (for dermatitis) 282,283 in patients with HIES.…”

Section: Combined B-and T-cell Immunodeficienciesmentioning

confidence: 99%

Practice parameter for the diagnosis and management of primary immunodeficiency

Bernstein¹,

Blessing-Moore²,

Khan³

et al. 2015

Journal of Allergy and Clinical Immunology

584

494

View full text Add to dashboard Cite

The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI) have jointly accepted responsibility for establishing the "Practice parameter for the diagnosis and management of primary immunodeficiency." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.

show abstract

“…Omalizumab is used for the treatment of moderate to severe persistent asthma in adults and adolescents older than 12 years of age who have elevated levels of IgE and positive skin test to a perennial allergen. Several studies reported clinical improvement in patients with severe atopic eczema with high serum IgE level [10–13]. However, prospective studies and long-term follow-up are required to confirm the efficacy of omalizumab in HIES.…”

Section: Discussionmentioning

confidence: 99%

Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome

Alonso-Bello

Jiménez-Martínez

Vargas-Camaño

et al. 2019

Case Reports in Immunology

View full text Add to dashboard Cite

Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level. We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab. After therapy for 4 years, we observed diminished eczema and serum IgE levels.

show abstract

Eczematous Dermatitis in the Setting of Hyper-IgE Syndrome Successfully Treated With Omalizumab

Cited by 35 publications

References 6 publications

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Practice parameter for the diagnosis and management of primary immunodeficiency

Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome

Contact Info

Product

Resources

About